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Background: We conducted a case-control study of the
association between calcium channel blocker use and
gastrointestinal (GI) tract bleeding in hypertensive mem-
bers of a health maintenance organization.
Methods: Case patients (n =174) were treated hyper-
tensive health maintenance organization members hos-
pitalized for GI tract bleeding between January 1992 and
December 1994. Case patients were identified using
computerized diagnosis codes and were confirmed by
medical record review. Control subjects (n=771) were
treated hypertensive members selected from ongoing
studies at the health maintenance organization. Comput-
erized pharmacy data and medical records were used to
assess medication use and other risk factors for GI tract
bleeding.
Results: Compared with ß-blocker users, calcium chan-
nel blocker users had an age-, sex- and calendar year-
adjusted relative risk (RR) of GI tract bleeding of 2.60
(95% confidence interval [CI], 1.71-3.96). The RR as-
sociated with calcium channel blocker use was 2.05 (95%
CI, 1.33-3.17) afterfurtheradjustmentfornumberofre-
cent visits, diastolic blood pressure, chronic congestive
heart failure, and duration of hypertension. No signifi-
cant dose-response relationship was observed. Com-
pared with ß-blocker users, angiotensin-converting en-
zyme Inhibitor users had an RR of 1.22 (95% CI,
0.75-1.97). Calcium channel blocker use tended to be
more strongly associated with risk of lower GI tract bleed-
ing (RR, 2.56; 95% CI, 1.08-6.05) than with risk of up-
per GI tract bleeding (RR, 1.54; 95% CI, 0.91-2.59) or
peptic ulcer-related bleeding (RR, 1.17; 95% CI, 0.62-
2.21), although these results were compatible with chance.
Conclusions: Calcium channel blocker use might be as-
sociated with an elevated risk of GI tract bleeding. These
findings require confirmation in randomized studies.
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A LTHOUGH the results ofsome observational stud-ies1'2 suggest that use ofcalcium channel blockersmight be associated with
an approximately 2-fold increased risk of
gastrointestinal (GI) tract bleeding, other
studies3"5 have not confirmed this find-
ing. Each of the 3 major calcium channel
blocker subclasses has been shown to in-
hibit platelet function in experimental
studies.6"10 Calcium channel blocker
therapy also has a vasodilatory effect that
might interfere with the normal vasocon-
strictive response to bleeding.11 It is there-
fore biologically plausible that calcium
channel blocker therapy might increase the
risk of GI tract bleeding, although whether
it does so in practice remains an unan-
swered question.
Various methodological features may
explain why the epidemiological studies
conducted to date have not been consis-
tent. Some studies3 have examined GI tract
bleeding caused by a particular underly-
ing pathological condition, such äs pep-
tic ulcer disease, whereas others1 have in-
cluded bleeding from a variety of GI tract
lesions. Some studies1·4 have relied solely
on computerized diagnosis codes to iden-
tify individuals with GI tract bleeding, al-
though unvalidated diagnosis codes for GI
tract bleeding may have poor predictive
value.12 Information on the presence of hy-
pertension and other cardiovascular dis-
eases has often been unavailable, and con-
sequently it was not possible in some
previous studies3'5 to limit the study popu-
lation to patients who had an indication
for calcium channel blocker therapy. In
contrast, other studies1 have included only
individuals being treated for hyperten-
sion with calcium channel blockers or
other medications.
We conducted a case-control study
of the association between the use of cal-
cium channel blockers and the risk of hos-
pitalized upper or lower GI tract bleed-




STUDY POPULATION AND SETTING
The setting for this study was Group Health Cooperative
(GHC) of Fuget Sound, a health maintenance organiza-
tion based in Seattle, Wash, with more than 500000 mem-
bers. This was an ancillary study to an ongoing case-
control study of cardiovascular disease conducted in
pharmacologically treated hypertensive patients at GHC.13
For the analyses presented herein, we drew control sub-
jects from among treated hypertensive patients who were
identified for the main study and we identified case pa-
tients with GI tract bleeding who were also treated for hy-
pertension. The time frarne for this study wasjanuary 1992
through December 1994, which predates the published stud-
ies1 that raised concern about the safety of calcium chan-
nel blocker use.
SUBJECTS
Case patients were treated hypertensive GHC patients aged
30 to 79 years who were hospitalized for upper or lower
GI tract bleeding between January 1992 and December 1994.
We identified potential case patients from computerized
GHC hospital discharge records and Washington state death
files using the following International Classification ofDis-
eases, Ninth Revision,14 diagnosis codes: gastric, duodenal,
peptic, or gastrojejunal ulcer with bleeding (531.0, 531.2,
531.4,531.6,532.0,532.2,532.4,532.6,533.0,533.2,533.4,
533.6, 534.0, 534.2, 534.4, and 534.6); bleeding of rec-
tum or anus (569.0); hematemesis (578.0); melena (578.1);
or GI tract bleeding not otherwise specified (578.9). We
specified in advance that the antihypertensive medica-
tions of interest for this study would be angiotensin-
converting enzyme (ACE) inhibitors, ß-blockers, and cal-
cium channel blockers, and we included äs potential case
patients only those who had filled a prescnption for one
of these medications during the 4 months preceding hos-
pitalization for GI tract bleeding, according to GHC's com-
puterized pharmacy database.
We reviewed discharge summaries and other Infor-
mation in the outpatient medical records maintained by
GHC to confirm that all case patients had evidence of GI
tract bleeding noted at or within a few days of hospital ad-
mission. We did not include bleeding that was a compli-
cation of surgery or a procedure, and we included only the
first episode of bleeding if more than one occurred during
the study. Using Information in the medical records, we
confirmed that case patients were being treated with medi-
cations for hypertension, that they were aged 30 to 79 years,
and that they had made at least 4 previous visits to a GHC
provider.
Control subjects were treated hypertensive patients
aged 30 to 79 years who were enrolled at GHC between
January 1992 and December 1994. We required that the
controls had filled a recent prescription for an ACE inhibi-
tor, ß-blocker, or calcium channel blocker and that ac-
cording to the medical records they were being treated for
hypertension, were within the proper age ränge, and had
made 4 previous visits to a GHC provider. In the main study
that served äs the source of our control population, con-
trols were a stratified random sample of GHC patients with
hypertension who were frequency matched by sex, age, and
year to incident cases of myocardial infarction and stroke.13
Control subjects with previous myocardial infarction or
stroke were included in this analysis.
INDEX DATES
Each subject was assigned an index date. The index date
for case patients was the date of hospital admission for GI
tract bleeding and for control subjects was a randomly se-
lected date during the year for which they were selected äs
a control.
COLLECTION OF DATA ON MEDICATION USE
AND OTHER RISK FACTORS
The computerized GHC pharmacy database served äs the pri-
mary source of Information for assessing the use of antihy-
pertensive and other prescription medications. The phar-
macy database contains a record of every drug prescription
ing in health maintenance organization patients being
treated for hypertension.
RESULTS
We reviewed 381 potential case patients with GI tract bleed-
ing and determined that 174 met eligibility criteria and were
current users of one of the antihypertensive medications
of interest on the index date. We identified 771 control
subjects who were similarly eligible for this study. Cases
were slightly older and had a lower proportion of men than
controls, and these differences in age and sex reflect the
use of controls from a parent study (Table 1). Com-
pared with controls, case patients had more recent visits;
lower mean diastolic blood pressure and body mass in-
dex; and more preexisting diseases, including diabetes
mellitus, chronic congestive heart failure, previous myo-
cardial infarction, pulmonary disease, chronic liver dis-
ease, and alcoholism. Cases were more likely than con-
trols to be current smokers or to be physically inactive.
Use of salicylate and ibuprofen did not differ between cases
and controls, and use of other NSAIDs, oral corticoste-
roids, and anticoagulants and recent thrombolytic therapy
were more common in cases than controls.
Among control subjects, current users of calcium
channel blockers were older than users of ß-blockers or
ACE inhibitors (Table 2). Use of aspirin and other sa-
licylates was more common among calcium channel
blocker users (46.0%) than among ß-blocker users
(43.3%) or ACE inhibitor users (33.9%). Other charac-
teristics of the drug user groups in Table 2 reflect rela-
tive contraindications or indications other than hyper-
tension for use of ß-blockers, ACE inhibitors, and calcium
channel blockers, including angina, diabetes mellitus,
claudication, congestive heart failure, chronic obstruc-
tive pulmonary disease, and asthma.
Compared with current users of ß-blockers, cur-
rent users of calcium channel blockers had an age-, sex-
and year-adjusted RR of GI tract bleeding of 2.60 (95%
confidence interval [CI], 1.71-3.96) (Figure 1). After fur-
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dispensed at a GHC pharmacy and includes information on
the type of drug, pill strength, quantity, dosing instruc-
tions, and dispensing date. According to a telephone survey
conducted äs part of a previous study, 94.5% of GHC en-
rollees filled "all or almost all" prescriptions at a GHC phar-
macy.15 For the antihypertensive medications of interest, we
defined current users äs those who filled a prescription that
would be expected to last until the index date, assuming that
patients were 80% compliant with the dosing instructions.
We also identified subjects who had started using calcium
channel blockers or other agents within 6 months before the
index date.
We defined subjects äs users of oral corticosteroids or
oral anticoagulant agents if they filled a prescription for these
medications within 45 days before the index date. We used
the medical records to determine whether subjects had re-
ceived thrombolytic therapy within the 2 weeks before the
index date or whether heparin was administered during the
index hospitalization. We defined subjects äs users of sa-
licylates or other nonsteroidal anti-inflammatory drugs
(NSAIDs) if the medical records noted that they were us-
ing these medications regularly at the index date or if they
filled 2 or more prescriptions for these medications dur-
ing the year before the index date.
Other risk factors for GI tract bleeding were recorded
by trained abstractors using the medical records from the
period before, but not including, the index date. Records
abstractors were not masked to case-control Status or medi-
cation use, although they were unaware of the study hy-
pothesis.
STATISTICAL ANALYSES
We estimated the relative risk (RR) of GI tract bleeding in
current users of calcium channel blockers and in current
users of ACE inhibitors compared with current users of
ß-blockers. Subjects using more than l of these antihyper-
tensive medications were excluded from this study. We also
estimated the RRs associated with use of specific calcium
channel blocker agents with doses that were less than, equal
to, or greater than the modal daily doses used by the study
population (240 mg for verapamil, 180 mg for diltiazem,
30 mg for nifedipine, 60 mg for nicardipine, and 5 mg for
amlodipine) and with recently starting use of calcium chan-
nel blockers.
We conducted separate analyses for upper and lower
GI tract bleeding, peptic ulcer-associated bleeding, and
bleeding that was "life threatening" (complicated by circu-
latory shock, surgical Intervention, transfusion of 3 U or
more of blood, death, or "severe blood loss" äs noted in
the medical record). We did not have a particular a priori
hypothesis regarding which etiologic subtypes of bleed-
ing would be most strongly associated with calcium chan-
nel blocker use. We also estimated RRs in subgroups
defined by age (above or below the median of 68 years),
sex, diabetes Status, smoking Status, and use of other med-
ications associated with GI tract bleeding (NSAIDs, oral
corticosteroids, or anticoagulants).
We estimated RRs by odds ratios derived from mul-
tivariate logistic regression models computed using Stata
5.0.16 We included age, sex, and year of index date äs ad-
justment variables, in addition to other potential risk fac-
tors for hospitalized GI tract bleeding that modified the RRs
of interest when added to the multivariate models. We ex-
amined the following risk factors äs potential confound-
ers: use of oral corticosteroids, NSAIDs, and anticoagu-
lants; race (white vs nonwhite); number of visits in the year
before the index date; duration of enrollment at GHC; re-
cent systolic and diastolic blood pressures (mean of up to
3 readings); current angina; duration of treated hyperten-
sion, pharmacologically treated diabetes mellitus; claudica-
tion; chronic congestive heart failure; previous myocardial
infarction; chronic obstructive pulmonary disease; asthma;
current smoking; alcohol consumption (none, occasional, or
heavy); current or history of alcoholism; chronic liver dis-
ease; physical activity (active vs not active); current marital
Status; weight; height; and body mass index. Risk factor mea-
surements were missing for fewer than 5% of subjects for
all variables except alcohol consumption (12% missing).
We used multiple imputation for handling missing data
and a "hot deck" approach for selecting imputed val-
ues.17 Similar results were obtained when we repeated
the analyses after excluding subjects with missing values
of covariates.
ther adjustment for number of visits in the previous year,
diastolic blood pressure, chronic congestive heart failure,
and duration of treated hypertension, the RR associated
with calcium channel blocker use was 2.05 (95% CI,
1.33-3.17). Compared with current users of ß-blockers, cur-
rent users of ACE inhibitors did not have a significantly
increased risk of GI tract bleeding after adjustment for risk
factors (RR, 1.22; 95% CI, 0.75-1.97). Further adjust-
ment for other risk factors had little effect on the RRs
after we adjusted for number of visits, diastolic blood pres-
sure, chronic congestive heart failure, and duration of
hypertension (Table 3).
The adjusted RR of GI tract bleeding was l .48 for sub-
jects using calcium channel blockers at doses lower than
the modal doses, 2.29 for those using the modal doses of
calcium channel blockers, and 2.16 for those using cal-
cium channel blockers at doses greater than the modal doses
compared with ß-blocker users (P=.22 for trend)
(Figure 2). The RR was similar in subjects using verap-
amil (RR, 2.06 compared with ß-blocker users), diltia-
zem (RR, 1.73), and nifedipine (RR, 2.38) (Figure 2). Sub-
jects using immediate-release calcium channel blockers had
a similar RR äs those using sustained-release calcium chan-
nel blockers (RR, 2.01 for immediate-release agents; and
RR, 2.47 for sustained-release agents) (Figure 2).
Twenty-five subjects (12 cases and 13 controls) had
started using calcium channel blockers within 6 months
before the index date and, compared with ß-blocker us-
ers, these recent Starters of calcium channel blocker
therapy had an adjusted RR of 5.12 (95% CI, 2.06-
12.70) (data not shown). After removing recent Starters
of calcium channel blocker therapy from the analysis, cal-
cium channel blocker users remained at elevated risk of
GI tract bleeding compared with ß-blocker users (RR,
1.81; 95% CI, 1.17-6.87). We examined whether there
was an association between recently starting use of other
antihypertensive agents and higher risk of GI tract bleed-
ing. Thirty subjects (6 cases and 24 controls) had started
using ACE inhibitors within 6 months before the index
date, and these subjects had a similar risk of GI tract bleed-
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Table 1. Characteristics of Gase Patients With Hospitalized
Gastrointestinal Tract Bleeding and Control Subjects
Among Hypertensive Patients Enrolled at GHC,
January 1992 to December 1994*
Characteristlc




Visits in previous year, mean (SD), No.f
Duration of enrollment at GHC, mean
(SD),y
Duration of treated hypertension, mean
(SD),y
Systolic blood pressure, mean (SD),
mm Hg
Diastolic blood pressure, mean (SD),
mmHgt




Chronic congestive heart failure, %t
Previous myocardial infarction, %t
COPD or asthma, %t
Chronic liver disease, %t
Cancer within the previous 2 y, %
Current or history of alcoholism, %t








Other NSAID use, %t
Oral corticosteroid use. %t
Reccnt thrombolytic therapy or































































*GHC indicates Group Health Cooperative; COPD, chromc obstructive
pulmonary disease; and NSAID, nonsteroidal anti-inflammatory drug.
fP<.05 by t lest for continuous variables and χ2 lest for categoncal
variables.
ing äs other users of ACE inhibitors (adjusted RR, 0.90;
95% CI, 0.33-2.47). Eighteen subjects (4 cases and 14
controls) had recently started using ß-blockers, and these
subjects had an adjusted RR of 1.75 (95% CI, 0.53-5.80)
compared with other users of ß-blockers.
We repeated the analysis for subtypes of GI tract
bleeding defined by anatomical location, cause, and
severity (Figure 3). Use of calcium channel blockers
tended to be more strongly associated with risk of lower
GI tract bleeding (RR, 2.56; 95% CI, 1.08-6.05 [35 case
patients]) than the risk of upper GI tract bleeding (RR,
1.54; 95% CI, 0.91-2.59 [98 case patients]). Calcium
channel blocker users had an RR of 1.17 (95% CI, 0.62-
2.21) for bleeding caused by peptic ulcer (58 case
patients, all but l confirrned by endoscopy). The RR
associated with calcium channel blocker use was 2.28
for life-threatening bleeding (52 case patients) and 1.98
for non-life-threatening bleeding (122 case patients).
Although these analyses suggested differences in the RRs
for subtypes of bleeding, the differences were compatible
with chance.
Relative risks were of similar magnitude and did not
differ significantly among subgroups defined by age, sex,
diabetes, smoking, or use of other medications known
to be associated with GI tract bleeding (NSAIDs, oral cor-
ticosteroids, or anticoagulants). After we excluded 93 cases
and 282 controls with a relative contraindication or an
indication other than hypertension for use of one of the
antihypertensive medications of interest, the adjusted RRs
were 2.58 (95% CI, 1.50-4.45) for calcium channel blocker
use and 1.13 (95% CI, 0.69-1.84) for ACE inhibitor use
compared with ß-blocker use. The RRs were similar af-
ter we excluded 65 subjects with a diagnosis of cancer
within the 2 years before the index date (RR, 2.09; 95%
CI, 1.32-3.31 for calcium channel blocker use and RR,
1.28; 95% CI, 0.77-2.12 for ACE inhibitor use) and af-
ter we excluded 36 subjects who were users of antico-
agulants or who received thrombolytic therapy in the 2
weeks before the reference date (RR, 1.87; 95% CI, 1.20-
2.92 for calcium channel blocker use and RR, 1.26; 95%
CI, 0.77-2.05 for ACE inhibitor use).
COMMENT
In this observational study, hypertensive patients whö were
current users of calcium channel blockers had approxi-
mately a 2-fold higher risk of hospitalized upper or lower
GI tract bleeding than hypertensive patients who used
ß-blockers. Users of ACE inhibitors did not have a sig-
nificandy higher risk of GI tract bleeding than patients who
used ß-blockers. The association between use of calcium
channel blockers and higher risk of GI tract bleeding per-
sisted after adjustment for risk factors recorded from medi-
cal records and also after adjustment for use of other medi-
cations that might cause GI tract bleeding.
Despite our efforts to adjust for known risk factors
for GI tract bleeding, residual confounding might have been
present. We relied on Information from medical records
and computerized pharmacy data to measure use of aspi-
rin and other NSAIDs. Because patients can take these medi-
cations without the knowledge of their physician and can
purchase them without a prescription, it is likely that we
did not identify all users. The antihypertensive medica-
tions examined in this study might sometimes be used to
treat conditions that might be related to GI tract bleeding
(eg, calcium channel blockers for esophageal motility dis-
orders18 and ß-blockers for esophageal varices19). How-
ever, all subjects in this study were being treated for hy-
pertension, and these additional indications would be
expected to be relatively uncommon.
The first population-based study1 to suggest that use
of calcium channel blockers might have an adverse ef-
fect on the risk of GI tract bleeding was conducted among
hypertensive patients in the Established Populations for
Epidemiologie Studies of the Elderly cohort. In that study,
users of calcium channel blockers had an RR of hospi-
talized or fatal upper or lower GI tract bleeding of 1.86
(95% CI, 1.22-2.82) compared with users of ß-block-
ers. More recently, 3 well-conducted observational stud-
ies did not demonstrate a strong association between cal-
cium channel blocker use and confirrned bleeding caused
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Table 2. Characteristics of Control Subjects According to Current Use of Antihypertensive Medications*
Characteristic




Visits in previous year, mean (SD), No.t
Duration of enrollment at GHC, mean (SD), yf
Duration of treated hypertension, mean (SD), yt
Systolic blood pressure. mean (SD), mm Hgf
Diastolic blood pressure, mean (SD), mm Hgf




Chronic congestive heart failure, %t
Previous myocardial infarction, %
COPD or asthma, %f
Chronic liver disease, %
Cancer within the previous 2 y, %
Current or history of alcoholism, %








Other NSAID use, %
Oral corticosteroid use, %































































































*ACE indicates angiotensin-converting enzyme Inhibitor; GHC, Group Health Cooperative; COPD, chronic obstructive pulmonary disease; and NSAID,
nonsteroidal anti-inflammatory drug.
fP<.05 for overall difference between drug use groups, by analysis of variance for continuous variables and χ2 fesf for categorical variables.
by peptic ulcer and other diseases of the upper GI tract.
Smalley and colleagues3 reported an RR of hospitalized
bleeding peptic ulcer of 1.1 (95% CI, 0.7-1.7) for users
of calcium channel blockers compared with nonusers.
Kelly and colleagues5 reported an RR of major upper GI
tract bleeding of 1.2 (95% CI, 0.9-1.6) for calcium chan-
nel blocker use compared with nonuse. In a third study20
conducted in Italy, current use of calcium channel block-
ers compared with nonuse was associated with an RR of
hospitalized upper GI tract bleeding of 1.4 (95% CI, 1.1-
1.8), although the authors interpreted this result with cau-
tion because past use and current use of calcium chan-
nel blockers were associated with an elevated RR.
These studies reporting negative findings included
only upper GI tract bleeding outcomes, whereas our study
examined lower and upper GI tract bleeding. This dif-
ference is perhaps important. We found that calcium chan-
nel blocker use tended to be more strongly associated with
risk of lower GI tract bleeding (RR, 2.56; 95% CI, 1.08-
6.05) than risk of upper GI tract bleeding (RR, l .54; 95%
CI, 0.91-2.59) or peptic uker-related bleeding (RR, 1.17;
95% CI, 0.62-2.21). The differences between these RRs
were compatible with chance. However, these analyses
suggest that our results might be consistent with those
of previous studies that have shown only a weak asso-
ciation between calcium channel blocker use and upper
Gases, Controls,
No No Total
ß-BlockerUse 40 291 331
ACE Inhibitor Use 49 230 279










0.5 10 2.0 40
Adjusted Relative Risk and 95% CI
D Adjusted for Age, Sex, and Index Year
• Adjusted for Age, Sex, Index Year, No of Visits m Previous Year, Diastolic Blood
Pressure, Chronic Congestive Heart Failure, and Duration of Treated Hypertension
Figure 1. Association between current use of antihypertensive agents and
risk of hospitalized gastrointestinal tract bleeding. CI indicates confidence
interval; ACE, angiotensin-converting enzyme.
GI tract bleeding. The smaller RR for upper GI tract bleed-
ing might be because upper GI tract bleeding is rela-
tively more common than lower GI tract bleeding among
middle-aged persons.21 Experimental studies22·23 have
shown that calcium channel blockers might affect intes-
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Table 3. Association Between Current Use of Antihypertensive Agents and Risk of Hospitalized Gastrointestinal Tract Bleeding
After Adjustment for Selected Potential Confounders*












Sex, age, and index year
All of the above, plus visits in the previous year
All of the above, plus diastolic blood pressure
All of the above, plus chranic congestive heartfailure
All of the above, plus duratlon of treated hypertension
All of the above, plus salicylate use
All of the above, plus jbuprofen use
All of the above, plus other NSAID use

































*CI mdicates confidence mterval; ACE, angiotensin-convertmg enzyme; and NSAID, nonsteroidal anti-mflammatoiy drug.
•\Model 5 corresponds to the multivanate-adiusted model presented m Figure 1.
Gases, Controls,
No No
ß-BlockerUse 40 291 l
Calcium Channel
Blocker Use
Below Modal 20 81
Daily Dose
Modal Daily Dose 36 99
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D Adiusted for Age, Sex, and Index Year
• Adjusted for Age, Sex, Index Year, No of Visits in Previous Year, Diastolic Blood
Pressure, Chronic Congestive Heart Failure and Duration of Treated Hypertension
Figure 2. Association between calcium channel blocker use and nsk of
gastromtestmal tract bleed/ng by dose, drug type, and release formulation
For dose analyses, 7 cases and 12 controls with unknown dose were
excluded For drug type analyses, 2 cases and 4 controls usmg calcium
channel blockers other than verapamil, diltiazem, or mfedipme or more than
1 of these agents were excluded Cl mdicates confidence mterval.
tinal function, and this suggests that there might be a
pathophysiological explanation for the strong associa-
tion with lower GI tract bleeding.
Figure 3. Association between calcium channel blocker use and nsk of
gastromtestmal (Gl) tract bleeding by charactenstics of the bleeding event
The location ofthe bleeding was unknown for 41 cases For non-peptic ulcer
bleeding, 61 cases with unknown bleeding location or with upper
gastromtestmal tract bleeding with unknown etio/ogy were excluded. The
data are for calcium channel blocker use compared with β -adrenergic
blockmg agent use Cl mdicates confidence mterval
Like previous investigators,24 25 we did not find that
use of higher daüy doses of calcium channel blockers was
associated with greater bleeding nsk. Given the strong over-
all relationship between calcium channel blocker use and
bleeding, the lack of a dose-response pattern is unex-
pected. The RR was simüar for sustained-release and im-
mediate-release formulations of calcium channel block-
ers and for each of the major subclasses. Subjects who
started using calcium channel blockers within the previ-
ous 6 months had a risk of GI tract bleeding that was ap-
proximately 5 times higher than that of the comparison
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group of ß-blocker users Patients who switched antihy-
pertensive medications or who did not regularly fül their
prescnptions were hkely to be classmed äs recent Starters
accordmg to the defmition we used and these patients
might tend to be m poorer health There was not strong
evidence m our data, however, that recent Starters of other
antihypertensive medications had a markedly elevated nsk
of GI tract bleedmg although the number of subjects avaü-
able for these analyses was small The fmdmg of a higher
RR for recent Starters of calcmm channel blocker use
than among long-term users might reflect a drug effect that
becomes attenuated after contmuous use
Because of the possibility of bias, the results of ob-
servaüonal studies such äs this one should be inter-
preted cautiously Randomrzed climcal tnals are less sus-
ceptible to bias, but at this time the available data from
chnical studies do not provide an adequate evaluation
of the nsk of bleedmg associated with calcium channel
blockers The Syst-Eur trial did not suggest an excess of
reported bleedmg events among patients treated with
mtrendipme compared with placebo (19 vs 20 events
P= 74) 26 Because of the small number of events, the
results of the Syst-Eur trial were compatible at the 95%
confidence level, with a 52% lower and a 69% higher rate
of bleedmg among patients randomized to mtrendipme
Furthermore, because Syst-Eur and other climcal studies27
were mounted bef ore the first reports of a prohemorrhagic
effect of calcmm channel blocker therapy these studies
were not designed to collect Information on bleedmg m a
prospective manner
Results of this observational study suggest an asso-
ciation between calcium channel blocker use and
higher risk of GI tract bleedmg Studies conducted to
date have not been consistent, and this might be
because of differences in how cases of bleedmg were
defmed or other methodological differences Ongomg
climcal tnals28 provide the opportumty to collect pro-
spectively defmed bleedmg end pomts, and when com-
pleted, these studies might help clarify the risks and
benefits associated with calcium channel blocker
therapy for hypertension
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